Multiple Myeloma
You are here:
Myeloma has been plagued for a long time by inadequate risk stratification and insufficient testing. With the ability to perform testing on as little as 1 nanogram per ul of DNA, PlasmaSEQ ensures that physicians get the most information possible from the least amount of biological material.
Moreover, as PlasmaSEQ is a DNA only assay, it is much more tolerant to environment stresses and logistics of sample transport.
With 500X depth targeted coverage it may detect mutations in clones as low as 1.3%*.
